B. Dirks

发表

Double-Blind , Placebo-Controlled Study Behaviors and Clinician-and Informant-Rated ADHD Symptoms in Adults : Data From a Randomized , Treatment With Lisdexamfetamine Dimesylate Improves Self-and Informant-Rated Executive Function

L. Adler, R. Weisler, L. Ginsberg, 2014 .

Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder

R. Weisler, Thomas Babcock, G. Mattingly, 2013, BMC Psychiatry.

Original article Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylatetreatmentinadults

T. Brown, Thomas Babcock, M. Gasior, 2011 .

Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity

L. Adler, Thomas Babcock, L. Ginsberg, 2011, Current medical research and opinion.

Clinical Response and Symptomatic Remission in Children Treated With Lisdexamfetamine Dimesylate for Attention-Deficit/Hyperactivity Disorder

J. McGough, R. Findling, Thomas Babcock, 2010, CNS Spectrums.

Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate.

R. Findling, Thomas Babcock, L. Ginsberg, 2013, Journal of child and adolescent psychopharmacology.

Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD

B. Robertson, J. Ramos-Quiroga, J. Newcorn, 2018, European Child and Adolescent Psychiatry.

Attention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylate.

R. Weisler, Thomas Babcock, G. Mattingly, 2012, Innovations in clinical neuroscience.

Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.

L. Adler, R. Weisler, B. Dirks, 2013, The Journal of clinical psychiatry.

ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years

Thomas Babcock, V. Arnold, F. López, 2017, Journal of attention disorders.

Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis

R. Shelton, M. Fava, M. Trivedi, 2020, Depression and anxiety.

Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.

C. Kosik‐Gonzalez, R. Mahmoud, A. Kalali, 2009, The American journal of psychiatry.

Safety and Pharmacokinetics of Lisdexamfetamine Dimesylate in Adults With Clinically Stable Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial of Ascending Multiple Doses

M. Corcoran, Patrick Martin, B. Dirks, 2014, Journal of clinical psychopharmacology.

Adjunctive Lisdexamfetamine Dimesylate Therapy in Adult Outpatients With Predominant Negative Symptoms of Schizophrenia: Open-Label and Randomized-Withdrawal Phases

H. Nasrallah, J. Lindenmayer, Joseph Gao, 2013, Neuropsychopharmacology.

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia

I. Turkoz, B. Dirks, C. Bossie, 2008, Neuropsychiatric disease and treatment.

Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate

R. Findling, Thomas Babcock, A. Turgay, 2012, Journal of attention disorders.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).

R. Shelton, M. Fava, M. Trivedi, 2019, The Journal of clinical psychiatry.

Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study

Thomas Babcock, B. Dirks, B. Adeyi, 2012, BMC Pharmacology and Toxicology.

Analysis of individual items on the attention-deficit/hyperactivity disorder symptom rating scale in children and adults: the effects of age and sex in pivotal trials of lisdexamfetamine dimesylate

L. Adler, S. Kollins, R. Weisler, 2013, Neuropsychiatric disease and treatment.

Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study

R. Shelton, M. Fava, M. Trivedi, 2020, International clinical psychopharmacology.

Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study

L. Adler, R. Weisler, K. Saylor, 2013, BMC Psychiatry.

Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults

T. Wigal, T. Brown, Thomas Babcock, 2011, Current medical research and opinion.

Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.

R. Findling, Thomas Babcock, A. Turgay, 2010, Journal of child and adolescent psychopharmacology.

Efficacy and Safety of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder and Recent Methylphenidate Use

Thomas Babcock, B. Dirks, B. Adeyi, 2013, Advances in Therapy.

Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis

Thomas Babcock, B. Dirks, B. Adeyi, 2011, Child and adolescent psychiatry and mental health.

Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY.

R. Shelton, M. Fava, M. Trivedi, 2020, The Journal of clinical psychiatry.

Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study

L. Adler, R. Weisler, L. Ginsberg, 2017, Journal of attention disorders.

Sex subgroup analysis of treatment response to lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorder.

J. McGough, R. Findling, Thomas Babcock, 2012, Journal of clinical psychopharmacology.

The Effects of Lisdexamfetamine Dimesylate on Emotional Lability in Children 6 to 12 Years of Age With ADHD in a Double-Blind Placebo-Controlled Trial

Thomas Babcock, V. Arnold, A. Childress, 2014, Journal of attention disorders.

ADHD in a Double-Blind Placebo-Controlled Trial The Effects of Lisdexamfetamine Dimesylate on Emotional Lability in Children 6 to 12 Years of Age With

Thomas Babcock, V. Arnold, A. Childress, 2013 .

Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

J. Newcorn, A. Hervás, M. Huss, 2019, European Neuropsychopharmacology.

Interpreting ADHD Rating Scale Scores: Linking ADHD Rating Scale Scores and CGI Levels in Two Randomized Controlled Trials of Lisdexamfetamine Dimesylate in ADHD

S. Faraone, L. Adler, R. Weisler, 2010 .

Exposure–response Modeling From the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder

J. Passarell, D. Jaworowicz, M. Darwish, 2023, Clinical pharmacology in drug development.

Treatment outcomes with lisdexamfetamine dimesylate in children who have attention-deficit/hyperactivity disorder with emotional control impairments.

R. Findling, Thomas Babcock, B. Dirks, 2013, Journal of child and adolescent psychopharmacology.

Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate

R. Findling, Thomas Babcock, A. Turgay, 2012, Journal of attention disorders.

Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity

L. Adler, Thomas Babcock, L. Ginsberg, 2011, Current medical research and opinion.